|
Salukhov V.V., Shustov S.B., Petrankov K.V.
Advantages of combined use of sodium-glucose co-transporter type 2 inhibitors and glucagon-like peptide-1 receptor agonists relatively to cardiovascular and renal outcomes in patients with type 2 diabetes mellitus
|
№8 / 2024
|
|
Shchemeleva E.V., Skorodumova E.A.
Febuxostat: Efficacy and safety of the drug, prospects for application (literature review)
|
№5 / 2024
|
|
Alieva A.M., Nikitin I.G., Teplova N.V., Baykova I.E., Rakhaev A.M., Kudaeva M.V., Sozaeva M.R., Kotikova I.A.
Diagnostic and therapeutic aspects of irisin in cardiovascular pathology and metabolic disorders
|
№9 / 2023
|
|
Larina V.N., Lankin A.O., Larin V.G., Golovko M.G.
Modern viewpoint at prediabetes: Prevalence, diagnostic criteria, risk groups, screening
|
№9 / 2023
|
|
Livzan M.A., Bikbavova G.R., Safiulina T.A., Loginova E.N.
Gut microbiome modulation and cardiovascular risks: Mechanisms of formation and correction
|
№8 / 2023
|
|
Lopukhov S.V., Nikiforov A.A., Filippov E.V.
Calculation of cardiovascular risk in patients with premature ovarian insufficiency depending on its etiology
|
№6 / 2023
|
|
Ponomareva E.Yu., Sedov D.S.
Left-sided infectious endocarditis in a patient receiving program hemodialysis treatment
|
№4 / 2023
|
|
Rebrov A.P., Tyapkina M.A., Ordyakova A.A., Yupatov V.D., Kosheleva N.A., Basov I.V.
Patients with cardiovascular diseases and NSAIDs intake: Is there a real problem today?
|
№4 / 2023
|
|
|
№3 (приложение) / 2023
|
|
|
№3 (приложение) / 2023
|
|
|
№3 (приложение) / 2023
|
|
|
№3 (приложение) / 2023
|
Русский
